Rotavirus News and Research

Latest Rotavirus News and Research

Researchers identify novel viral sensor complex

Double-stranded (ds) RNA viruses are a diverse group of viruses that include rotaviruses, a common cause of gastroenteritis. The ability of the immune system to detect and destroy viruses is critical for human health and survival.

24 Jun 2011

Developing new antipoverty vaccines may eliminate world's neglected diseases, says Sabin president

Despite significant advancements in increasing distribution and development of vaccines against childhood killer diseases - including pneumococcal disease, rotavirus, and Haemophilus influenzae Type B - global efforts to reduce the burden of infection from neglected tropical diseases (NTDs) has greatly lagged, argues Sabin Vaccine Institute (Sabin) President Dr. Peter Hotez in an article for the June edition of Health Affairs.

23 Jun 2011

New vaccines on the horizon

In a report published in The Lancet, researchers say there is the potential to develop 20 new or improved vaccines over the next decade. They emphasize that funding is crucial - but so is trust and confidence in vaccines. It is said that AIDS and malaria vaccines as the most important areas for research. Authors further suggest that neglected tropical diseases, such as leprosy, should also be investigated.

9 Jun 2011

Scientists, advocacy experts form new international Foundation for Vaccine Research

Fourteen leading scientists and advocacy experts in vaccines and infectious diseases have announced the formation of a new international Foundation to advance and accelerate vaccine research and development against infectious diseases.

9 Jun 2011

Several drug makers plan to lower prices of vaccines for GAVI purchase

Several pharmaceutical companies have pledged to lower the prices of vaccines against childhood illnesses ahead of the GAVI Alliance conference in London next week, the Guardian reports (Quinn, 6/6).

6 Jun 2011

Bharat Biotech announces the pricing for ROTAVAC vaccine

Bharat Biotech today announced the price of ROTAVAC India’s first indigenously developed Rotavirus Vaccine. The vaccine will be sold to global public markets, Governments worldwide including UN procurement agencies at a price of US $ 1.0. Bharat Biotech hopes its new vaccine will help prevent part of the ~ 500,000 child deaths each year caused due to rotavirus diarrhea and improve access to better, affordable rotavirus vaccines.

6 Jun 2011

GAVI welcomes lower pentavalent vaccine price

In the lead up to its first pledging conference on June 13, the GAVI Alliance announced today it has achieved commitments from two emerging market vaccine manufacturers to lower prices for the life-saving pentavalent vaccine, which protects against five deadly diseases. Developed country manufacturers have also offered price reductions on rotavirus and human papillomavirus, or HPV, vaccines.

5 Jun 2011

Experts to present latest information on paediatric infectious diseases at ESPID 2011

The Annual ESPID Meeting has become the world's largest meeting in the field of Paediatric Infectious Diseases (PID): it provides the latest information on the number one threat to global child health.

1 Jun 2011

Afghan Acting Health Minister says country wants to boost immunization access

Reuters featured an interview with Afghanistan's Acting Health Minister Suraya Dalil on the sidelines of the World Health Assembly in Geneva. "Afghanistan, whose government is fighting a worsening insurgency that has dragged on for nearly a decade since the U.S.-backed overthrow of the Taliban, is also plagued by poverty, malnutrition and corruption," Reuters writes, adding that the government and donors together spend "barely" $10 per person on health annually.

19 May 2011

Early childhood food allergies increase risk of severe allergy-related conditions and asthma later in life

Early results from the largest cross-sectional national allergy study ever conducted, to be released later this month, demonstrate that food allergies commonly occur in infants and toddlers, while environmental allergies, such as to dust, ragweed and mold, are more common in older children and adults.

From Quest Diagnostics 18 May 2011

Haiti presents plan to immunize 90 percent of newborns

Haiti has a plan to vaccinate 90 percent of newborns by 2015, according to PAHO, but "whether the plan works will depend on Haiti's ability to reverse decades of incompetent government and bad coordination among aid groups," as well as whether there will be funding, the New York Times reports.

18 May 2011

iOWH, Center for World Health and Medicine partner to combat childhood diarrhea

The Center for World Health and Medicine at Saint Louis University and the Institute for OneWorld Health have established a joint research agreement to develop new drugs to combat diarrhea, which is the second leading cause of death worldwide in children under age 5.

4 May 2011

Merck and Sanofi Pasteur commence Phase III trial of pediatric hexavalent combination vaccine

Merck and Sanofi Pasteur, the vaccines division of sanofi-aventis Group, announced today the initiation of a Phase III clinical program to evaluate the safety and immunogenicity of an investigational pediatric hexavalent combination vaccine.

21 Apr 2011

Synexus' Chief Medical Officer to discuss vaccine trial challenges at Washington event

Dr Glynis Neagle, Synexus' Chief Medical Officer will be discussing the challenges facing global vaccine trials at the World Vaccine Congress in Washington this week.

From AES - Accelerated Enrollment Solutions 11 Apr 2011

Immunization does not increase emergency room visit in children with inherited disorders

Children with inborn errors of metabolism received vaccines on the same immunization schedule as did healthy infants, according to Kaiser Permanente Vaccine Study Center scientists who examined the Kaiser Permanente Northern California population. In addition, immunization was not associated with significant increases in emergency room visits or hospitalizations during the month following vaccination, according to Nicola Klein, MD, PhD, lead author of the study and co-director of the Kaiser Permanente Vaccine Study Center.

11 Apr 2011

Lancet Infectious Diseases examines how resource gaps are creating barriers to reduce child mortality

The Lancet Infectious Diseases' Newsdesk examines how resource gaps in immunizations, health workers and financing are creating barriers to efforts to achieve the U.N. Millennium Development Goal target to reduce child mortality by two-thirds by 2015, as highlighted in a recent Save the Children report.

3 Mar 2011

Synexus creates specialist vaccines team to help pharma and biotech companies

Synexus has created a specialist vaccines team to help pharma and biotech companies find the thousands of patients they need for their late phase trials. The company has a well-established reputation for delivering results in the vaccine field following successes in late phase vaccine trials including most recently, studies for cancer prevention, influenza and rotavirus where it has delivered in excess of three thousand randomised patients in all three areas.

From AES - Accelerated Enrollment Solutions 21 Feb 2011

GAVI chair calls for greater reductions in vaccine prices for developing countries

On Monday, the same day the GAVI Alliance helped oversee the roll out of a routine pneumococcal vaccine in Kenya, GAVI chairman Dagfinn Hoybraten highlighted the need for greater reductions in vaccine prices in developing countries during an interview with Reuters, the news service reports. The piece examines the funding mechanism in place to finance the pneumococcal vaccines, known as Advance Market Commitment (AMC), as well as the budget shortfall facing the group (Kelland, 2/14).

16 Feb 2011

New study shows economic burden of dengue in Western Hemisphere is $2.1 billion per year

Dengue illness, the most common mosquito-borne viral disease in the world, has expanded from its Southeast Asian origins and is resurgent in countries such as Argentina, Chile and the continental United States.

8 Feb 2011

Study finds total cost of dengue illness in Americans to be $2.1 billion per annum

The first assessment of the total cost of dengue illness in the Americas reveals the economic burden to be approximately $2.1 billion per year, exceeding that from other viral illnesses including human papillomavirus and rotavirus.

4 Feb 2011

Rotavirus News and Research

Latest Rotavirus News and Research

Researchers identify novel viral sensor complex

Developing new antipoverty vaccines may eliminate world's neglected diseases, says Sabin president

New vaccines on the horizon

Scientists, advocacy experts form new international Foundation for Vaccine Research

Several drug makers plan to lower prices of vaccines for GAVI purchase

Bharat Biotech announces the pricing for ROTAVAC vaccine

GAVI welcomes lower pentavalent vaccine price

Experts to present latest information on paediatric infectious diseases at ESPID 2011

Afghan Acting Health Minister says country wants to boost immunization access

Early childhood food allergies increase risk of severe allergy-related conditions and asthma later in life

Haiti presents plan to immunize 90 percent of newborns

iOWH, Center for World Health and Medicine partner to combat childhood diarrhea

Merck and Sanofi Pasteur commence Phase III trial of pediatric hexavalent combination vaccine

Synexus' Chief Medical Officer to discuss vaccine trial challenges at Washington event

Immunization does not increase emergency room visit in children with inherited disorders

Lancet Infectious Diseases examines how resource gaps are creating barriers to reduce child mortality

Synexus creates specialist vaccines team to help pharma and biotech companies

GAVI chair calls for greater reductions in vaccine prices for developing countries

New study shows economic burden of dengue in Western Hemisphere is $2.1 billion per year

Study finds total cost of dengue illness in Americans to be $2.1 billion per annum

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Rotavirus News and Research

Latest Rotavirus News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in